7/5/23, 10:21 AM Atrial flutter: Maintenance of sinus rhythm - UpToDate Official reprint from UpToDate www.uptodate.com 2023 UpToDate, Inc. and/or its affiliates. All Rights Reserved. Atrial flutter: Maintenance of sinus rhythm : Jordan M Prutkin, MD, MHS, FHRS : Bradley P Knight, MD, FACC : Nisha Parikh, MD, MPH All topics are updated as new evidence becomes available and our peer review process is complete. Literature review current through: Jun 2023. This topic last updated: May 30, 2023. INTRODUCTION Atrial flutter is a relatively common supraventricular arrhythmia that can impact quality of life and cause stroke or systemic embolization. Restoration and maintenance of sinus rhythm improves symptoms and decreases the risk of embolization if atrial flutter recurrence does not occur. (See "Overview of atrial flutter", section on 'Clinical manifestations' and "Embolic risk and the role of anticoagulation in atrial flutter", section on 'Embolic risk'.) Issues related to the indications and therapeutic options for the maintenance of sinus rhythm in atrial flutter will be reviewed here. Causes of atrial flutter, rate control therapy, the restoration of sinus rhythm after cardioversion, and the role of anticoagulation in atrial flutter are discussed separately. (See "Overview of atrial flutter", section on 'Etiology and risk factors' and "Restoration of sinus rhythm in atrial flutter" and "Embolic risk and the role of anticoagulation in atrial flutter" and "Control of ventricular rate in atrial flutter".) INDICATIONS We attempt to keep most patients with recurrent atrial flutter in sinus rhythm to decrease symptoms, unlike atrial fibrillation (AF) in which rhythm control and rate control are reasonable strategies. In addition, the long-term maintenance of sinus rhythm may decrease the risk of stroke. Rhythm control with either radiofrequency (RF) catheter ablation or antiarrhythmic drug therapy is necessary; in most cases, RF catheter ablation is preferred because of the high rate of success and low rate of complications. Exceptions include individuals identified as having https://www.uptodate.com/contents/atrial-flutter-maintenance-of-sinus-rhythm/print 1/17 7/5/23, 10:21 AM Atrial flutter: Maintenance of sinus rhythm - UpToDate reversible triggers such as pneumonia, hyperthyroidism, and other acute medical problems. (See "Management of atrial fibrillation: Rhythm control versus rate control".). Atrial flutter is characterized by rapid, regular atrial depolarizations at a characteristic rate of approximately 300 beats/min. In the absence of rate slowing drugs or atrioventricular (AV) nodal disease, every other depolarization passes through the AV node, and the ventricular rate is usually around 150 beats per minute. Unlike AF, attempts to slow this rate are often unsuccessful or require high doses of rate slowing drugs; thus, the maintenance of sinus rhythm is desirable in most patients to control symptoms. In addition, episodes will often be recurrent unless a reversible cause is present. (See "ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias", section on 'Atrial fibrillation and atrial flutter' and "Overview of atrial flutter".) The discussion in this topic pertains primarily to patients with typical atrial flutter. The pathogenesis of typical atrial flutter makes it highly amendable to curative therapy with radiofrequency (RF) catheter ablation, though atypical flutters may also be cured with RF ablation. Typical (also called isthmus-dependent) atrial flutter utilizes a large macroreentrant pathway in the right atrium, with the left atrium following passively. (See "Electrocardiographic and electrophysiologic features of atrial flutter".) The negative deflection of the flutter (F) wave in lead II coincides in time with the impulse activating the low right atrial tissue between the inferior vena cava and the tricuspid valve. Activation then travels anteriorly through the region of the low septum, and superiorly and anteriorly up the medial surface of the right atrium, returning along the lateral wall of the right atrium back to the cavotricuspid isthmus (CTI) [1-6]. The cavotricuspid isthmus between the inferior vena cava and the tricuspid annulus (IVC-TA isthmus) is an obligatory route for typical flutter, and, as such, is the best anatomic target for ablation ( waveform 1A-B) [2-5,7-15]. RF CATHETER ABLATION For patients with typical atrial flutter in whom a decision is made to maintain sinus rhythm, radiofrequency catheter ablation is usually preferred to pharmacologic therapy. Technique The femoral approach is generally used and, under fluoroscopic guidance or using a three-dimensional mapping system, an ablation catheter is placed at the CTI where a large ventricular and small atrial electrogram are recorded. RF energy is applied, and the catheter is slowly withdrawn to create a line of ablation from the annulus to the inferior vena cava. https://www.uptodate.com/contents/atrial-flutter-maintenance-of-sinus-rhythm/print 2/17 7/5/23, 10:21 AM Atrial flutter: Maintenance of sinus rhythm - UpToDate The goal is to create a complete ablation line with the absence of electrical conduction across the CTI both medially to laterally and laterally to medially. This is the best marker for long-term success ( waveform 1A-B). If the patient presents in typical atrial flutter, CTI block should still be assessed with differential pacing on both sides of the ablation line after termination of atrial flutter, since frequently there can still be conduction across the CTI [16,17]. An infusion of isoproterenol during pacing may help to assess the completeness of isthmus block [18]. Alternatively, adenosine may also be given to assess for block across the line [19]. Another method for ablation is the maximum voltage technique [20]. Coronary sinus (CS) ostial pacing is completed and the largest amplitude atrial signal in the CTI is ablated as a point lesion. The next largest signal is then targeted, and the process is repeated until block is seen across the isthmus. Electroanatomic mapping is used in many cases for identifying the appropriate target area for ablation; it is a nonfluoroscopic three-dimensional mapping system. This system permits reconstruction of cardiac anatomy without the use of fluoroscopy. A study of 50 patients with atrial flutter compared isthmus ablation using conventional fluoroscopy for catheter positioning to positioning with electromagnetic mapping [21]. The success rate for complete isthmus blockade after 20 RF pulses or 25 minutes of fluoroscopy time was greater with electromagnetic mapping (96 versus 67 percent). Electromagnetic mapping significantly reduced the overall fluoroscopic time (4 versus 22 minutes) and the fluoroscopic time needed for isthmus mapping (0.2 versus 17.7 minutes). Ablation guided by intracardiac echocardiography (ICE) can also be used, and may be helpful to assess for pouches and ridges in the CTI during difficult cases or repeat procedures [10]. Outcome The initial success rate for RF catheter ablation of typical atrial flutter has ranged from 65 to 100 percent [22,23]. A meta-analysis of a 21 studies examining atrial flutter success rate suggested a single procedure success of 92 percent and multiple procedure success rate of 97 percent [24]. Recurrent atrial flutter or fibrillation Between 7 and 44 percent of patients who undergo flutter ablation have recurrent atrial arrhythmia, though the recurrent arrhythmia is usually AF [22,23]. Thus, some patients should undergo surveillance for recurrent atrial flutter or AF. Our approach to surveillance for recurrent arrhythmia is as follows. For patients who were initially symptomatic and who did not develop a tachycardia mediated cardiomyopathy, we perform testing to document recurrent arrhythmia only for symptoms. If the patient was initially asymptomatic, we perform periodic examinations (every 12 months) at which time we obtain an electrocardiogram, Holter, or event monitor. For those patients who developed tachycardia- https://www.uptodate.com/contents/atrial-flutter-maintenance-of-sinus-rhythm/print 3/17 7/5/23, 10:21 AM Atrial flutter: Maintenance of sinus rhythm - UpToDate mediated cardiomyopathy, standard heart failure therapy is still indicated unless otherwise contraindicated. Follow-up assessment of left ventricular function by imaging techniques such as echocardiography is warranted. We obtain a repeat echocardiogram three to six months after initiation of therapy. The rate of recurrent AF appears to depend upon the presence or absence of AF before the procedure. In a study of 100 patients, 29 of whom had documented AF before the procedure, AF occurred in 36.4 percent of those with complete follow-up after a mean of almost 15 months [25]. However, in another study of approximately 100 patients without pre-existent AF, new onset AF developed in only 12.9 percent during a mean follow-up of 19 months [26]. Most patients (92 percent) who develop AF after flutter ablation do so within six months. The risk may be as low as 10 percent (mean follow-up of 20 months) in those with no prior AF and a left ventricular ejection fraction >50 percent [27]. The likely reasons for the difference in the rates of recurrence likely has to do with differing populations being studied (eg, symptomatic versus asymptomatic patients) and the intensity of follow-up. In a study of 363 patients who underwent RF ablation for typical atrial flutter, 82 percent developed drug refractory AF during a follow-up period of 39 (+/- 11) months [28]. Elimination of atrial flutter may delay, but does not prevent AF and the two may share common triggers. Therefore, patients may derive a better long-term benefit from additional anatomical ablative treatment, lifestyle modifications, and/or pharmacological therapy of AF. (See 'Patients with atrial fibrillation' below.) Improvement in left ventricular function Persistent atrial flutter can result in a tachycardia-mediated left ventricular cardiomyopathy, similar to what has been seen with AF and other arrhythmias. On the other hand, reversal of the arrhythmia can result in improvement in left ventricular ejection fraction and, in 6 of 11 patients in one report, restoration of normal function [29]. (See "Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm" and "Arrhythmia-induced cardiomyopathy", section on 'Atrial fibrillation and atrial flutter'.) Quality of life RF ablation improves the quality of life and reduces symptoms in patients with atrial flutter, particularly if there is no associated AF [23,30]. Other benefits include a reduced frequency of hospitalizations, emergency department visits, need for cardioversion, and the need for antiarrhythmic drugs [31]. Safety RF catheter ablation of atrial flutter is significantly safer than that for atrial fibrillation, in part because the left atrium is not entered and because the procedure is generally shorter due to the fact that ablation in a very limited area that is not adjacent to vulnerable structures https://www.uptodate.com/contents/atrial-flutter-maintenance-of-sinus-rhythm/print 4/17 7/5/23, 10:21 AM Atrial flutter: Maintenance of sinus rhythm - UpToDate such as the esophagus and pulmonary veins [32]. (See "Atrial fibrillation: Catheter ablation", section on 'Complications'.) Pericardial effusion, atrioventricular block, and vascular access complications occur infrequently [33]. Procedure-related mortality is very rare and was 0 percent in a meta-analysis of 12 studies [24]. RF ablation versus pharmacologic therapy With the high success rate of radiofrequency (RF) catheter ablation for treating atrial flutter and its low complication rate, pharmacologic therapy is increasingly being replaced by ablation as the preferred strategy in most patients. Improved outcomes with ablation, compared to drug therapy, were illustrated in a randomized trial of 61 patients with at least two episodes of symptomatic atrial flutter within a four-month period [34]. The patients were assigned to conventional antiarrhythmic drug therapy or catheter ablation as a first line treatment. After a mean follow-up of 21 months, the following significant benefits were noted in the patients undergoing ablation: More were in sinus rhythm (80 versus 36 percent with drugs; P<0.01). Fewer required rehospitalization (22 versus 63 percent). Fewer developed AF (29 versus 53 percent). Sense of well-being and function during daily life activities improved with ablation but did not change with drugs. PHARMACOLOGIC THERAPY For most patients with atrial flutter, pharmacologic therapy is not chosen for the long-term maintenance of sinus rhythm. The success rate at one year has been estimated at only 20 to 30 percent, with the risk of recurrence highest in the patient with an enlarged right atrium who is in heart failure. Good prognostic signs for maintaining sinus rhythm are normal atrial size, recent onset, little or no heart failure, and an underlying reversible disorder such as hyperthyroidism, myocardial infarction, or pulmonary embolism. For patients in whom an attempt will be made to maintain sinus rhythm with antiarrhythmic drug therapy, we use the following drugs (with suggested starting doses): dronedarone 400 mg twice daily; flecainide 50 to 100 mg twice daily with an atrioventricular nodal agent; sotalol 80 mg twice daily; dofetilide 500 microgram twice daily; or amiodarone. Our reviewers have differing preferences as to the order in which these are tried. The drugs that are most likely to maintain sinus rhythm are the same as those used for rhythm control in atrial fibrillation (AF) ( algorithm 1). They act by suppressing triggering beats and https://www.uptodate.com/contents/atrial-flutter-maintenance-of-sinus-rhythm/print 5/17 7/5/23, 10:21 AM Atrial flutter: Maintenance of sinus rhythm - UpToDate arrhythmias and affecting atrial electrophysiologic properties. In a meta-analysis that included 36 patients, flecainide was 50 percent effective in the maintenance of sinus rhythm over variable follow-up [35]. Flecainide can also slow down the atrial flutter rate; thus, atrioventricular (AV) nodal agents should always be used in conjunction to prevent one-to-one atrial flutter. (See "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations", section on 'Selecting an antiarrhythmic drug'.) Oral dofetilide, a class III antiarrhythmic drug available for use in the United States, may be more effective than other agents for maintaining sinus rhythm. In the SAFIRE-D trial, which included 48 patients with atrial flutter, the probability of maintaining sinus rhythm at one year with dofetilide at a dose of 125, 250, or 500 mcg twice daily was 0.40, 0.37, and 0.58 versus 0.25 for placebo [36]. Dronedarone has been studied for the use of atrial flutter, though the major studies all included patients with AF also. In a trial of 2327 patients with AF or atrial flutter who were randomly assigned to either dronedarone 400 mg twice daily or placebo, dronedarone reduced the chances of recurrent AF or flutter by 25 percent and prolonged the time to first recurrence from 498 to 737 days [37]. In those with atrial flutter who had a recurrence, the mean heart rate was reduced by six beats/min, reflecting its rate control properties also. PATIENTS WITH ATRIAL FIBRILLATION Many patients with atrial flutter also have episodes of atrial fibrillation (AF). For many of these patients who have chosen ablation, we recommend atrial fibrillation (with or without atrial flutter ablation) ablation rather than atrial flutter ablation alone. The electrophysiologic substrates of AF and atrial flutter are different, and the addition of atrial flutter ablation to AF ablation adds very little risk. However, in some cases, we believe it is reasonable to perform atrial flutter ablation alone, particularly if atrial flutter is the predominant rhythm and if the rate in flutter is difficult and causing most symptoms. (See "Atrial fibrillation: Catheter ablation".) The optimal approach to ablation in patients with both atrial flutter and atrial fibrillation was evaluated in the single-blind APPROVAL trial, which randomly assigned 360 patients to ablation of AF (with or without atrial flutter ablation) or ablation of flutter alone [38]. Among patients in the first group, 124 received AF ablation only and 58 had both ablation procedures. At nearly 22 months of follow-up, patients assigned to the group that received AF ablation (with or without atrial flutter ablation) had a higher rate of primary end point of freedom from arrhythmia off antiarrhythmic drug therapy during follow-up (64 versus 19 percent). This outcome was similar for the two subpopulations in the first group (AF ablation with or without atrial flutter ablation). https://www.uptodate.com/contents/atrial-flutter-maintenance-of-sinus-rhythm/print 6/17 7/5/23, 10:21 AM Atrial flutter: Maintenance of sinus rhythm - UpToDate Patients in group one had significant improvement in scores on most quality-of-life measures, whereas those in group two did not. The finding in APPROVAL of similar outcomes between patients who received both AF and atrial flutter ablation and those who received AF ablation alone was noted in an earlier study of 108 patients with both AF and typical atrial flutter who were randomly assigned to either a dual ablative procedure (pulmonary vein isolation [PVI] and CTI ablation, 49 patients) or PVI alone (59 patients) [39]. These findings suggest that pulmonary vein triggers appear to initiate atrial flutter as well as AF. This conclusion is consistent with evidence that atrial flutter commonly starts after a transitional rhythm of variable duration, usually AF [40,41]. (See "Electrocardiographic and electrophysiologic features of atrial flutter".) ANTICOAGULATION The discussion of anticoagulation below focuses on patients who undergo radiofrequency (RF) catheter ablation. However, similar issues apply to patients with atrial flutter (and atrial fibrillation) in whom antiarrhythmic drug therapy is to be started. Any therapy that causes conversion of atrial flutter (or fibrillation) to sinus rhythm leads to a measurable increase in the short-term risk of embolization unless proper anticoagulation is in place. (See "Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation".) Anticoagulation before RF catheter ablation For patients in atrial flutter scheduled to under RF ablation, anticoagulation is handled, broadly speaking, in a manner similar to that for patients with atrial fibrillation who undergo cardioversion. Most of these patients require at least three to four weeks of adequate anticoagulation before the procedure. (See "Restoration of sinus rhythm in atrial flutter", section on 'Anticoagulation' and "Embolic risk and the role of anticoagulation in atrial flutter", section on 'Radiofrequency catheter ablation'.) For those patients with atrial flutter of less than 48 hours duration, there is disagreement whether a transesophageal echocardiogram (TEE) is necessary to exclude the presence of a left atrial thrombus, as there is not good quality evidence available. If a TEE is performed and no thrombus is found, RF catheter ablation may be performed without prior anticoagulation. For low-risk patients with atrial flutter of less than 48 hours, it may be reasonable to proceed with ablation without a TEE. (See "Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation", section on 'AF duration less than 48 hours'.) https://www.uptodate.com/contents/atrial-flutter-maintenance-of-sinus-rhythm/print 7/17 7/5/23, 10:21 AM Atrial flutter: Maintenance of sinus rhythm - UpToDate If the patient is not in atrial flutter at the time of the ablation, therapeutic anticoagulation is not necessary and a TEE is not usually performed. Anticoagulation after RF catheter ablation Anticoagulation for the prevention of embolic events may be necessary, at least on a temporary basis, after flutter ablation due to the potential for the development of recurrent atrial flutter or AF within six months. However, there are limited data to support this approach [42]. We use the following approach: We recommend oral anticoagulation for all patients for at least four weeks after atrial flutter ablation if they were in atrial flutter at the start of the ablation. For patients with evidence of recurrent atrial flutter after atrial flutter ablation, with atrial fibrillation before or after the flutter ablation, or for those patients in sinus rhythm at the time of the ablation, we use the CHA2DS2-VASc score to determine the long-term need for anticoagulation. This may include using no anticoagulation in those at low risk. This issue is discussed in detail elsewhere. (See "Atrial fibrillation: Catheter ablation", section on 'Periprocedural embolic events'.) SOCIETY GUIDELINE LINKS Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Atrial fibrillation" and "Society guideline links: Arrhythmias in adults".) SUMMARY AND RECOMMENDATIONS Indications We attempt to maintain sinus rhythm in most patients with recurrent atrial flutter to decrease symptoms and prevent complications. Unlike atrial fibrillation, the alternative strategy of rate control is usually unsuccessful. (See 'Indications' above.) Radio frequency ablation For most patients with typical atrial flutter in whom a rhythm control strategy is desired, we recommend radiofrequency catheter ablation rather than a pharmacologic approach (Grade 1B). (See 'RF catheter ablation' above and 'RF ablation versus pharmacologic therapy' above.) For patients with both atrial flutter and fibrillation, we recommend radiofrequency catheter ablation of the atrial fibrillation and flutter rather than ablation of atrial flutter alone (Grade 1B). (See 'Patients with atrial fibrillation' above.) https://www.uptodate.com/contents/atrial-flutter-maintenance-of-sinus-rhythm/print 8/17 7/5/23, 10:21 AM Atrial flutter: Maintenance of sinus rhythm - UpToDate For those patients in whom atrial flutter is the predominant rhythm, atrial flutter ablation alone is a reasonable strategy. Importance of anticoagulation Anticoagulation around the time of radiofrequency catheter ablation or pharmacologic cardioversion is handled in a manner similar to that for patients with atrial flutter or fibrillation scheduled to undergo cardioversion. Most patients will require effective anticoagulation both before and after the procedure. (See 'Anticoagulation' above.) ACKNOWLEDGMENT The UpToDate editorial staff thank Dr. Jie Cheng, who contributed as an author to prior versions of this topic review. Use of UpToDate is subject to the Terms of Use. REFERENCES 1. Wells JL Jr, MacLean WA, James TN, Waldo AL. Characterization of atrial flutter. Studies in man after open heart surgery using fixed atrial electrodes. Circulation 1979; 60:665. 2. Klein GJ, Guiraudon GM, Sharma AD, Milstein S. Demonstration of macroreentry and feasibility of operative therapy in the common type of atrial flutter. Am J Cardiol 1986; 57:587. 3. Cosio FG, Arribas F, Barbero JM, et al. Validation of double-spike electrograms as markers of conduction delay or block in atrial flutter. Am J Cardiol 1988; 61:775. 4. Cosio FG, L pez-Gil M, Goicolea A, Arribas F. Electrophysiologic studies in atrial flutter. Clin Cardiol 1992; 15:667. 5. Olshansky B, Okumura K, Hess PG, Waldo AL. Demonstration of an area of slow conduction in human atrial flutter. J Am Coll Cardiol 1990; 16:1639. 6. Dixit S, Lavi N, Robinson M, et al. Noncontact electroanatomic mapping to characterize typical atrial flutter: participation of right atrial posterior wall in the reentrant circuit. J Cardiovasc Electrophysiol 2011; 22:422. 7. Touboul P, Saoudi N, Atallah G, Kirkorian G. Electrophysiologic basis of catheter ablation in atrial flutter. Am J Cardiol 1989; 64:79J. 8. Feld GK, Fleck RP, Chen PS, et al. Radiofrequency catheter ablation for the treatment of human type 1 atrial flutter. Identification of a critical zone in the reentrant circuit by https://www.uptodate.com/contents/atrial-flutter-maintenance-of-sinus-rhythm/print 9/17 7/5/23, 10:21 AM Atrial flutter: Maintenance of sinus rhythm - UpToDate endocardial mapping techniques. Circulation 1992; 86:1233. 9. Kirkorian G, Moncada E, Chevalier P, et al. Radiofrequency ablation of atrial flutter. Efficacy of an anatomically guided approach. Circulation 1994; 90:2804. 10. Olgin JE, Kalman JM, Fitzpatrick AP, Lesh MD. Role of right atrial endocardial structures as barriers to conduction during human type I atrial flutter. Activation and entrainment mapping guided by intracardiac echocardiography. Circulation 1995; 92:1839. 11. Poty H, Saoudi N, Abdel Aziz A, et al. Radiofrequency catheter ablation of type 1 atrial flutter. Prediction of late success by electrophysiological criteria. Circulation 1995; 92:1389. 12. Cauchemez B, Haissaguerre M, Fischer B, et al. Electrophysiological effects of catheter ablation of inferior vena cava-tricuspid annulus isthmus in common atrial flutter. Circulation 1996; 93:284. 13. Nath S, Mounsey JP, Haines DE, DiMarco JP. Predictors of acute and long-term success after radiofrequency catheter ablation of type 1 atrial flutter. Am J Cardiol 1995; 76:604. 14. Steinberg JS, Prasher S, Zelenkofske S, Ehlert FA. Radiofrequency catheter ablation of atrial flutter: procedural success and long-term outcome. Am Heart J 1995; 130:85. 15. Fischer B, Haissaguerre M, Garrigues S, et al. Radiofrequency catheter ablation of common atrial flutter in 80 patients. J Am Coll Cardiol 1995; 25:1365. 16. Poty H, Saoudi N, Nair M, et al. Radiofrequency catheter ablation of atrial flutter. Further insights into the various types of isthmus block: application to ablation during sinus rhythm. Circulation 1996; 94:3204. 17. Schwartzman D, Callans DJ, Gottlieb CD, et al. Conduction block in the inferior vena caval- tricuspid valve isthmus: association with outcome of radiofrequency ablation of type I atrial flutter. J Am Coll Cardiol 1996; 28:1519. 18. Nabar A, Rodriguez LM, Timmermans C, et al. Isoproterenol to evaluate resumption of conduction after right atrial isthmus ablation in type I atrial flutter. Circulation 1999; 99:3286. 19. Lehrmann H, Weber R, Park CI, et al. "Dormant transisthmus conduction" revealed by adenosine after cavotricuspid isthmus ablation. Heart Rhythm 2012; 9:1942. 20. Jacobsen PK, Klein GJ, Gula LJ, et al. Voltage-guided ablation technique for cavotricuspid isthmus-dependent atrial flutter: refining the continuous line. J Cardiovasc Electrophysiol 2012; 23:672. 21. Kottkamp H, H gl B, Krauss B, et al. Electromagnetic versus fluoroscopic mapping of the inferior isthmus for ablation of typical atrial flutter: A prospective randomized study. Circulation 2000; 102:2082. https://www.uptodate.com/contents/atrial-flutter-maintenance-of-sinus-rhythm/print 10/17 7/5/23, 10:21 AM Atrial flutter: Maintenance of sinus rhythm - UpToDate 22. Scheinman MM, Huang S. The 1998 NASPE prospective catheter ablation registry. Pacing Clin Electrophysiol 2000; 23:1020. 23. Calkins H, Canby R, Weiss R, et al. Results of catheter ablation of typical atrial flutter. Am J Cardiol 2004; 94:437. 24. Spector P, Reynolds MR, Calkins H, et al. Meta-analysis of ablation of atrial flutter and supraventricular tachycardia. Am J Cardiol 2009; 104:671. 25. Anselme F, Saoudi N, Poty H, et al. Radiofrequency catheter ablation of common atrial flutter: significance of palpitations and quality-of-life evaluation in patients with proven isthmus block. Circulation 1999; 99:534. 26. Ng DW, Altemose GT, Wu Q, et al. Typical atrial flutter as a risk factor for the development of atrial fibrillation in patients without otherwise demonstrable atrial tachyarrhythmias. Mayo Clin Proc 2008; 83:646. 27. Paydak H, Kall JG, Burke MC, et al. Atrial fibrillation after radiofrequency ablation of type I atrial flutter: time to onset, determinants, and clinical course. Circulation 1998; 98:315. 28. Ellis K, Wazni O, Marrouche N, et al. Incidence of atrial fibrillation post-cavotricuspid isthmus ablation in patients with typical atrial flutter: left-atrial size as an independent predictor of atrial fibrillation recurrence. J Cardiovasc Electrophysiol 2007; 18:799. 29. Luchsinger JA, Steinberg JS. Resolution of cardiomyopathy after ablation of atrial flutter. J Am Coll Cardiol 1998; 32:205. 30. Lee SH, Tai CT, Yu WC, et al. Effects of radiofrequency catheter ablation on quality of life in patients with atrial flutter. Am J Cardiol 1999; 84:278. 31. O'Callaghan PA, Meara M, Kongsgaard E, et al. Symptomatic improvement after radiofrequency catheter ablation for typical atrial flutter. Heart 2001; 86:167. 32. Bohnen M, Stevenson WG, Tedrow UB, et al. Incidence and predictors of major complications from contemporary catheter ablation to treat cardiac arrhythmias. Heart Rhythm 2011; 8:1661. 33. P rez FJ, Schubert CM, Parvez B, et al. Long-term outcomes after catheter ablation of cavo- tricuspid isthmus dependent atrial flutter: a meta-analysis. Circ Arrhythm Electrophysiol 2009; 2:393. 34. Natale A, Newby KH, Pisan E, et al. Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol 2000; 35:1898. 35. Hohnloser SH, Zabel M. Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. Am J Cardiol 1992; 70:3A. https://www.uptodate.com/contents/atrial-flutter-maintenance-of-sinus-rhythm/print 11/17 7/5/23, 10:21 AM Atrial flutter: Maintenance of sinus rhythm - UpToDate 36. Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000; 102:2385. 37. Page RL, Connolly SJ, Crijns HJ, et al. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). Am J Cardiol 2011; 107:1019. 38. Mohanty S, Mohanty P, Di Biase L, et al. Results from a single-blind, randomized study comparing the impact of different ablation approaches on long-term procedure outcome in coexistent atrial fibrillation and flutter (APPROVAL). Circulation 2013; 127:1853. 39. Wazni O, Marrouche NF, Martin DO, et al. Randomized study comparing combined pulmonary vein-left atrial junction disconnection and cavotricuspid isthmus ablation versus pulmonary vein-left atrial junction disconnection alone in patients presenting with typical atrial flutter and atrial fibrillation. Circulation 2003; 108:2479. 40. Waldo AL, Cooper TB. Spontaneous onset of type I atrial flutter in patients. J Am Coll Cardiol 1996; 28:707. 41. Waldo AL. Mechanisms of atrial flutter and atrial fibrillation: distinct entities or two sides of a coin? Cardiovasc Res 2002; 54:217. 42. Nunes-Ferreira A, Alves M, Lima da Silva G, et al. Anticoagulation after typical atrial flutter ablation: Systematic review and meta-analysis. Pacing Clin Electrophysiol 2021; 44:1701. Topic 1065 Version 27.0 https://www.uptodate.com/contents/atrial-flutter-maintenance-of-sinus-rhythm/print 12/17 7/5/23, 10:21 AM Atrial flutter: Maintenance of sinus rhythm - UpToDate GRAPHICS Intracardiac and surface ECG recordings during electrophysiologic study and radiofrequency catheter ablation of typical atrial flutter Three surface ECG leads (I, aVF, V1) and intracardiac recordings from the high right atrium (HRA), a mapping catheter in the isthmus between the tricuspid valve and inferior vena cava (TV-IVC) (HBE1-2), eight recordings from a catheter extending from the lateral right atrial wall through the TV-IVC isthmus and into the ostium of the coronary sinus (CS15-1 to CS1-2), and right ventricular apex (RVA3-4) in a patient with typical atrial flutter. The tip of the mapping catheter was initially positioned on the tricuspid annulus, and then dragged through the TV-IVC isthmus to the ostium of the IVC during RF application; atrial flutter terminated. Note that the atrial activation (A) blocks between CS7-8 and CS5-6, which on fluoroscopy corresponded to the position of the mapping catheter. Fl: flutter waves; V: ventricular electrogram. Graphic 69946 Version 4.0 https://www.uptodate.com/contents/atrial-flutter-maintenance-of-sinus-rhythm/print 13/17 7/5/23, 10:21 AM Atrial flutter: Maintenance of sinus rhythm - UpToDate Intracardiac and surface electrocardiogram (ECG) recordings during electrophysiologic study and radiofrequency catheter ablation of atrial flutter showing bidirectional isthmus block Shown are three surface ECG leads (I, aVF, V1) and intracardiac recordings from the high right atrium (HRA), eight recordings from a catheter extending from the lateral right atrial wall through the tricuspid valve-inferior vena cava (TV- IVC) isthmus and into the ostium of the coronary sinus (CS15-16 through CS1- 2), and right ventricular apex (RVA3-4) in a patient who has undergone ablation for atrial flutter. Left panel shows pacing (PA) from the lateral right atrial wall; the impulse is propagated down the lateral wall of the high right atrium, generating an atrial electrogram (A), to the lateral TV-IVC isthmus region (CS13- 14, CS11-12, CS9-10) where conduction is blocked. The medial aspect of the isthmus is not depolarized until a wavefront of activation comes down the interatrial septum or from the low left atrium; the distal poles of the catheter are therefore depolarized late and in the opposite direction, from the coronary sinus ostium back towards the medial TV-IVC isthmus (CS3-4, CS5-6, CS7-8). Right panel shows pacing from the coronary sinus ostium. In this case, the medial isthmus is depolarized promptly (CS3-4, CS5-6), but conduction is blocked within the isthmus (CS7-8). Thus, activation of the lateral wall of the right atrium is delayed until a wavefront travels up the septum and across the roof of the right atrium. Activation of the proximal poles of the catheter is therefore delayed and occurs from high to low (CS15-16, CS13-14, CS11-12, https://www.uptodate.com/contents/atrial-flutter-maintenance-of-sinus-rhythm/print 14/17 7/5/23, 10:21 AM Atrial flutter: Maintenance of sinus rhythm - UpToDate CS9-10). Patients with bidirectional block across the TC-IVC isthmus have a low rate of atrial flutter recurrence. Graphic 60090 Version 4.0 https://www.uptodate.com/contents/atrial-flutter-maintenance-of-sinus-rhythm/print 15/17 7/5/23, 10:21 AM Atrial flutter: Maintenance of sinus rhythm - UpToDate Maintenance of sinus rhythm Therapy to maintain sinus rhythm in patients with recurrent paroxysmal or persistent atrial fibrillation. Drugs are listed alphabetically and not in order of suggested use. The seriousness of heart disease progresses from left to right, and selection of therapy in patients with multiple conditions depends on the most serious condition present. LVH: left ventricular hypertrophy. Reproduced from: Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial brillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57:223. Illustration used with the permission of Elsevier Inc. All rights reserved. Graphic 83173 Version 2.0 https://www.uptodate.com/contents/atrial-flutter-maintenance-of-sinus-rhythm/print 16/17 7/5/23, 10:21 AM Atrial flutter: Maintenance of sinus rhythm - UpToDate Contributor Disclosures Jordan M Prutkin, MD, MHS, FHRS No relevant financial relationship(s) with ineligible companies to disclose. Bradley P Knight, MD, FACC Grant/Research/Clinical Trial Support: Abbott [Electrophysiology]; Atricure [Electrophysiology]; Biosense Webster [Electrophysiology]; Biotronik [Electrophysiology]; Boston Scientific [Electrophysiology]; BSCI [Electrophysiology]; MDT [Electrophysiology]; Philips [Electrophysiology]. Consultant/Advisory Boards: Abbott [Electrophysiology]; Atricure [Electrophysiology]; Biosense Webster [Electrophysiology]; Biotronik [Electrophysiology]; Boston Scientific [Electrophysiology]; BSCI [Electrophysiology]; CVRx [Heart failure]; MDT [Electrophysiology]; Philips [Electrophysiology]; Sanofi [Arrhythmias]. Speaker's Bureau: Abbott [Electrophysiology]; Biosense Webster [Electrophysiology]; Biotronik [Electrophysiology]; Boston Scientific [Transeptal catheterization]; BSCI [Electrophysiology]; MDT [Electrophysiology]. All of the relevant financial relationships listed have been mitigated. Nisha Parikh, MD, MPH No relevant financial relationship(s) with ineligible companies to disclose. Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence. Conflict of interest policy https://www.uptodate.com/contents/atrial-flutter-maintenance-of-sinus-rhythm/print 17/17